Cencora, Inc. $COR Shares Sold by Fjarde AP Fonden Fourth Swedish National Pension Fund

Fjarde AP Fonden Fourth Swedish National Pension Fund reduced its stake in Cencora, Inc. (NYSE:COR) by 8.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 118,677 shares of the company’s stock after selling 11,000 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund owned 0.06% of Cencora worth $40,083,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. AustralianSuper Pty Ltd bought a new position in shares of Cencora in the third quarter worth approximately $26,191,000. Chilton Investment Co. Inc. bought a new position in shares of Cencora in the third quarter worth approximately $459,000. Advisors Asset Management Inc. lifted its stake in shares of Cencora by 40.3% in the third quarter. Advisors Asset Management Inc. now owns 17,302 shares of the company’s stock worth $5,407,000 after buying an additional 4,973 shares in the last quarter. Lansforsakringar Fondforvaltning AB publ lifted its stake in shares of Cencora by 5.4% in the third quarter. Lansforsakringar Fondforvaltning AB publ now owns 60,254 shares of the company’s stock worth $18,831,000 after buying an additional 3,073 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Cencora by 4.0% in the third quarter. Rhumbline Advisers now owns 430,150 shares of the company’s stock worth $134,435,000 after buying an additional 16,539 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Up 1.7%

Shares of Cencora stock opened at $274.94 on Friday. The company has a market cap of $53.49 billion, a price-to-earnings ratio of 21.08, a price-to-earnings-growth ratio of 1.46 and a beta of 0.59. The company’s 50 day moving average is $292.70 and its 200 day moving average is $330.55. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. During the same quarter last year, the company earned $4.42 EPS. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Research analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora declared that its board has authorized a stock buyback program on Thursday, May 21st that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 3.9% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.9%. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Analysts Set New Price Targets

COR has been the topic of a number of research analyst reports. Citigroup lowered their price objective on shares of Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Evercore set a $360.00 price objective on shares of Cencora in a research report on Wednesday, April 8th. Robert W. Baird lowered their price objective on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. UBS Group increased their price objective on shares of Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, Weiss Ratings downgraded shares of Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 22nd. Twelve research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $380.25.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.